scholarly journals Theming, Co-Creation, and Quality of Structured Experiences at Camp

2019 ◽  
Vol 14 (1) ◽  
pp. 230-242 ◽  
Author(s):  
Gary D. Ellis ◽  
Jingxian Jiang ◽  
Andrew Lacanienta ◽  
Mark Carroll

Lacanienta and his colleagues (2018) recently reported results of a study of the effect of themes on quality of experience of youths during summer camp activities. Existing literature suggested that theming activity sessions would have a strong main effect. Results, though, revealed an activity-by-theme interaction effect, i.e., themes seem to be effective in some activities but not others. In this follow-up study, we describe results of a secondary analysis revealing significant new insights regarding theme. Adding an indicator of campers’ co-created, lived-experience theme into the models tested substantially clarified how objective theme, lived-experience theme, and activity interact in influencing the quality of structured experiences. This study, then, underscores the importance of including measures of participants’ co-created lived experience as we seek to understand techniques that can be used to enhance the quality of youths’ structured camp experiences.

Author(s):  
Min Min Tan ◽  
Daniel D. Reidpath ◽  
Rachel Sing-Kiat Ting ◽  
Pascale Allotey ◽  
Tin Tin Su

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii352-iii352
Author(s):  
Hung Tran ◽  
Robert Cooper

Abstract PURPOSE To describe decreased growth velocity with long term use of BRAFV600e and MEK inhibition in a patient with anaplastic ganglioglioma. RESULTS 4-year-old patient was found to have a 6 x 4.6 x 5 cm mass in the hypothalamus. Pathology consistent with anaplastic ganglioglioma and chromosomal microarray revealed a BRAFV600e mutation. Patient started on dabrafenib and trametinib and tumor decreased 85% after 3 months. She is stable without significant toxicities 39 months on therapy, and is now 8 years old. Patient had been growing at the 25% for weight and 12% for height but is now 65% for weight and 0.5% for height. It is difficult to tease out the relationship between the tumor, the location of the tumor, and the BRAF and MEK inhibitors and their effect on growth. Discussions with the family and endocrinology are ongoing but being <1% for height will lead to decrease in quality of life. CONCLUSIONS Further follow-up study is needed to determine if this is truly a long-term toxicity, or if this may just be a direct result of the location of the tumor. Would supplementation with growth hormone in this patient lead to losing control of a high grade tumor, or would it simply replace a hormone that is not produced?


2014 ◽  
Vol 15 (1) ◽  
Author(s):  
Paul Ruckenstuhl ◽  
Gerwin A Bernhardt ◽  
Patrick Sadoghi ◽  
Mathias Glehr ◽  
Lukas A Holzer ◽  
...  

2009 ◽  
Vol 10 (1) ◽  
Author(s):  
Inger Hallberg ◽  
Margareta Bachrach-Lindström ◽  
Staffan Hammerby ◽  
Göran Toss ◽  
Anna-Christina Ek

2017 ◽  
Vol 98 (10) ◽  
pp. e94
Author(s):  
Tzu-Ling Chang ◽  
Chia-Ling Chen ◽  
Chia-ying Chong

Sign in / Sign up

Export Citation Format

Share Document